BUD reports today with the most significant shift since the last preview now coming from options traders rather than short sellers.
The standout change heading into the print is a sharp defensive turn in options positioning. The put/call ratio has jumped to 0.795, nearly three standard deviations above its 20-day mean of 0.68 — a z-score of 2.99, the most elevated defensive reading in months. Four days ago the PCR was 0.65 and call-skewed; it has flipped hard toward puts in the final sessions before the release. That kind of late rotation into downside protection is often the clearest signal of hedging demand rather than outright bearishness, but the speed of the move is notable. The stock itself is little changed, down 1.6% on the week and off about 1% over the past month to $78.20, offering no obvious fundamental trigger for the options shift.
Short interest has continued building since the prior preview flagged a 37% monthly surge. The latest estimate puts shorts at roughly 8.3 million shares, up another 4% in a single session on September 21 after a brief mid-week dip. The month-on-month increase now reaches 34%. The borrow market has loosened considerably, however. Availability has expanded to 93%, well above the 42% trough hit on September 11, and the cost to borrow has edged up to 1.5% — still low in absolute terms despite a 13% weekly rise. That combination — growing short positions but easy borrow conditions — is consistent with fresh, low-friction bearish positioning rather than a stressed squeeze setup.
The analyst community remains broadly constructive, with a consensus mean price target around $97 implying meaningful upside to current levels. Wells Fargo reiterated Overweight and raised its target to $97 after the July print, while JPMorgan holds Overweight at $93.83. The one discordant note came from Barclays, which downgraded to Equal-Weight in late July without publishing a revised target. BUD's EPS surprise factor ranks in the 94th percentile, a strong historical beat rate that gives bulls a concrete basis for optimism. Bears can point to the 12-month forward EPS growth score ranking just 13th percentile — the Street sees limited earnings acceleration from here even if near-term execution is solid.
Ownership is tightly concentrated. The Stichting Anheuser-Busch InBev foundation controls 33.6% of shares, and both Altria and founder Jorge Paulo Lemann hold active Schedule 13D filings — activist-level disclosures, though both reflect long-standing strategic stakes rather than new pressure campaigns. Stakes are as last disclosed and may not reflect current positions. The last comparable earnings event in July produced a 1.9% one-day gain before fading to a 1.1% loss over the following five sessions — a pattern of initial relief giving way to modest pressure.
The print is therefore less a test of whether AB InBev can beat and more a test of whether management's volume and pricing commentary can justify a stock that the options market, for the first time in months, is approaching with genuine caution.
See the live data behind this article on ORTEX.
Open BUD on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
